

# ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant glioma

## Incidence

- The incidence of malignant glioma is 5–7/100 000. Malignant glioma may develop at all ages, the peak incidence being in the fifth and sixth decades of life.

## Diagnosis

- Malignant glioma comprises glioblastoma multiforme (WHO grade IV), anaplastic astrocytoma (WHO grade III), mixed anaplastic oligoastrocytoma (WHO grade III), and anaplastic oligodendroglioma (WHO grade III). Diagnosis after biopsy or tumor resection is made according to the revised WHO classification.

## Staging and risk assessment

- Staging includes imaging of the brain, ideally with MRI. If repeat imaging is deemed necessary to determine residual disease, it should be done within 24–48 h after surgery. Lumbar puncture is generally not necessary and staging of other organs is not needed.
- Other than tumor grade, good performance status and an intact neurological function, tumor resection, and age <50 years have been identified as more favorable prognostic factors.
- Prognosis depends on tumor grade. Glioblastoma carry the worst prognosis, while pure oligodendroglioma tend to have a better outcome and improved response to therapy. Mixed anaplastic oligoastrocytoma behave similarly to anaplastic astrocytoma with an intermediate prognosis.

## Treatment plan

- Patients should be evaluated by a specialized multidisciplinary team. Special consideration needs to be given to performance status and neurological function.

## Newly-diagnosed patients

- Surgery is commonly the initial therapeutic approach for debulking and obtaining tissue for diagnosis. Tumor resection is of prognostic value, but attempting maximal tumor resection remains controversial [IV, C]. Implantation of chemotherapy-impregnated wafer (BCNU-polymer) into the resection cavity has shown only a marginal benefit [II, B].
- Fractionated focal radiotherapy (60 Gy, 2 Gy ×30; or equivalent doses/fractionations) is the standard treatment after

resection or biopsy [I, A]. Escalating doses beyond 60 Gy has not been shown of value. In elderly patients or patients with a low performance status shorter hypofractionated regimens (e.g. 3 Gy ×10) are commonly proposed.

- Adjuvant chemotherapy with procarbazine, lomustine (CCNU) and vincristine (PCV regimen) has failed to improve survival in prospective randomized studies [I, A]. Nevertheless, based on a large meta-analysis [III, B] nitrosourea-based chemotherapy may improve survival in selected patients.
- Concomitant and adjuvant temozolomide chemotherapy has demonstrated to significantly improve median and 2-year survival in a large randomized trial [I, A]. Selecting patients likely to benefit from therapy based on *MGMT* gene methylation has been suggested [II, B].

## Recurrent disease

- Some benefit of chemotherapy has been shown for patients with an adequate performance status who have not received prior adjuvant cytotoxic therapy. Anaplastic astrocytomas are more likely to respond to chemotherapy than glioblastoma. [III, B].
- Repeat surgery and implantation of chemotherapy-impregnated polymers may prolong survival in selected patients [II, B].

## Oligodendroglioma

- Oligodendroglioma carry a somewhat better prognosis. In particular the subgroup of patients with a deletion on chromosome 1p and 19q seem to have a longer survival and better response to chemotherapy. However, at the current time 1p/19q LOH determination should not be routinely performed and should not influence the initial treatment recommendations. In patients with recurrent oligodendroglioma, chemotherapy should be considered [II, B].

## Response evaluation

- If response is evaluated, it should be done with MRI. Contrast enhancement and presumed tumor progression on imaging 4–8 weeks after the end of radiotherapy may be an imaging artifact due to changes in the blood-brain barrier permeability and should be confirmed 4 weeks later with a second MRI.
- Response to chemotherapy is evaluated according to the WHO criteria, but should also include an assessment of the neurological function and corticosteroid use (Macdonald criteria).

## Follow-up

- Follow-up consists of a clinical evaluation with particular attention to neurological function, seizures or seizure equivalents and corticosteroid use. Patients should be tapered off steroid use as early as possible.
- Laboratory tests are not indicated unless patient is receiving chemotherapy (blood counts), corticosteroids (glucose) or anti-epileptic drugs (blood counts, liver function tests).

## Note

Levels of Evidence [*I–V*] and Grades of Recommendation [*A–D*] as used by the American Society of Clinical Oncology are given in square brackets. Statements without grading were considered justified standard clinical practice by the expert authors and the ESMO faculty.

## Literature

1. DeAngelis LM. Medical Progress: Brain Tumors. *N Engl J Med* 2001; 344: 114–123.
2. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. *Lancet* 2002; 359: 1011–1018.
3. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council trial. *J Clin Oncol* 2001; 19: 509–518.
4. Stupp R, Mason WP, van den Bent MJ et al. on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and National Cancer Institute of Canada Clinical Trials Group. Concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme. *New Engl J Med* 2005; 352: 987–996.
5. Hegi ME, Diserens AC, Godard S et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. *Clin Cancer Res* 2004; 10: 1871–1874.
6. Westphal M, Hilt DC, Bortey E et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. *Neuro-oncol* 2003; 5: 79–88.
7. Yung WK, Albright RE, Olson J et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. *Br J Cancer* 2000; 83: 588–593.
8. Brandes AA, Tosoni A, Basso U et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). *J Clin Oncol* 2004; 22: 4727–4734.
9. van den Bent M, Chinot OL, Cairncross JG. Recent developments in the molecular characterization and treatment of oligodendroglial tumors. *Neuro-Oncol* 2003; 5: 128–138.
10. van den Bent MJ, Taphoorn MJ, Brandes AA et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26 971. *J Clin Oncol* 2003; 21: 2525–2528.
11. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. *J Clin Oncol* 1990; 8: 1277–1280.
12. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. *J Clin Oncol* 1999; 17: 2572–2578.
13. Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. *J Neurosurg* 2001; 95: 190–198.

Coordinating authors for the ESMO Guidelines Task Force: R. Stupp<sup>1</sup>, N. Pavlidis<sup>2</sup> & S. Jelic<sup>3</sup>

<sup>1</sup>Invited author, University Hospital (CHUV), Multidisciplinary Oncology Center, 1011 Lausanne, Switzerland; <sup>2</sup>Assigned task force member, University of Ioannina, Dept. Medical Oncology, 45 110 Ioannina, Greece; <sup>3</sup>Assigned task force member, Institute of Oncology and Radiology of Serbia, Department of Medical Oncology, Pasterova 14, 11000 Belgrade, Serbia

Approved by the ESMO Guidelines Task Force: December 2004.

*Correspondence to:*  
ESMO Guidelines Task Force  
ESMO Head Office  
Via La Santa 7  
CH-6962 Lugano  
Switzerland